GS1191-0445 injection

DRUG2 trials

Sponsors

Gritgen Therapeutics Co., Ltd.

Conditions

Hemophilia ASevere Hemophilia A

Phase 1

To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A

Active, not recruitingNCT07548411

Gritgen Therapeutics Co., Ltd.Severe Hemophilia A

Start: 2023-07-10End: 2029-12-23Updated: 2026-05-06

Phase 3

To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A

RecruitingNCT06833983

Gritgen Therapeutics Co., Ltd.Hemophilia A

Start: 2025-03-31End: 2030-11-30Target: 50Updated: 2025-12-09